Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05524935 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

Name: Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma — clinical trial record (NCT05524935)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 2

SponsorH. Lee Moffitt Cancer Center and Research Institute

Started2022-10-11

View on ClinicalTrials.gov ↗

This is a prospective phase II multi-center trial of the combination of the PARP inhibitor olaparib with the immune checkpoint inhibitor pembrolizumab in advanced uveal melanoma.

Amendment history 4 changes detected by DataLookout

2026-09-16

Primary completion pushed: 2026-07 → 2027-07

2026-06-23

Trial status changed: Recruiting → Active, Not Recruiting

2026-06-23

Enrollment reduced: 37 → 12 participants

2026-06-23

Primary completion moved earlier: 2026-12 → 2026-07

Trial Details

NCT Number	NCT05524935
Lead Sponsor	H. Lee Moffitt Cancer Center and Research Institute Collaborators: Merck Sharp & Dohme LLC
Conditions	Uveal Melanoma, Ocular Melanoma
Enrollment	12 participants
Start Date	2022-10-11
Primary Completion	2027-07 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-09-15